Tom Greenhalgh

By day, Tom Greenhalgh is an author for more than a dozen medical brands, where he writes easily-digestible content for clinicians and patients alike on medical breakthroughs and hot button issues. By night, he is an amateur music producer, avid sports fan, and Netflix connoisseur. Find him on LinkedIn or email him.

All articles by Tom Greenhalgh

Depressive Disorder

We Surveyed HCPs About CBD: 6 Key Takeaways

Tom Greenhalgh

November 5, 2019

We surveyed HCPs about CBD to find out if and how the phytocannabinoid is affecting practices across America.

Schizophrenia and Psychoses

Researchers Evaluate Smartphone Intervention for Schizophrenia Spectrum Disorders

Tom Greenhalgh

October 25, 2019

Researchers evaluated a smartphone intervention designed to manage lingering symptoms in schizophrenia spectrum disorders.

Ketamine, an anesthetic long known as a psychedelic and addictive street drug, has shown efficacy in treating individuals with depression that does not respond to standard treatments. In fact, certain academic medical centers offer ketamine infusions to patients with severe depression, and pharmaceutical companies are working on developing antidepressants inspired by the drug.1 Yet, while ketamine offers promise of a significant breakthrough in solving treatment-resistant depression, it remains a challenge for clinicians who are wary of the potential for abuse and dependence.2

Depression Advisor

Ketamine for Depression: Clinical Evidence and Concerns

Tom Greenhalgh

July 12, 2019

Ketamine is gaining ground as a promising option for treatment-resistant depression, but not every clinician is buying in. We review clinical evidence and concerns surrounding the drug.